
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.1 | -8.45503458878 | 13.01 | 13.09 | 11.62 | 725339 | 12.32387289 | CS |
4 | 2.57 | 27.5160599572 | 9.34 | 13.09 | 9.25 | 900601 | 11.35396138 | CS |
12 | -1.21 | -9.22256097561 | 13.12 | 13.57 | 8.18 | 965274 | 10.77740444 | CS |
26 | -8.55 | -41.788856305 | 20.46 | 21.67 | 8.18 | 880339 | 13.84018 | CS |
52 | -4.3 | -26.5268352869 | 16.21 | 29.56 | 8.18 | 865444 | 18.23891628 | CS |
156 | 2.35 | 24.5815899582 | 9.56 | 29.56 | 4.22 | 653866 | 14.53629095 | CS |
260 | -8.34 | -41.1851851852 | 20.25 | 52.38 | 4.22 | 544545 | 17.69300804 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions